{"id":7777,"date":"2020-11-12T11:50:04","date_gmt":"2020-11-12T11:50:04","guid":{"rendered":"https:\/\/www.innovationnewsnetwork.com\/?p=7777"},"modified":"2020-11-12T11:50:04","modified_gmt":"2020-11-12T11:50:04","slug":"fucoxanthin-compound-in-brown-seaweeds-show-promising-effects-when-treating-brain-cancer","status":"publish","type":"post","link":"https:\/\/www.innovationnewsnetwork.com\/fucoxanthin-compound-in-brown-seaweeds-show-promising-effects-when-treating-brain-cancer\/7777\/","title":{"rendered":"Fucoxanthin compound in brown seaweeds show promising effects when treating brain cancer"},"content":{"rendered":"
The EU-funded project GENIALG (GENetic diversity exploitation for Innovative macro-ALGal biorefinery) project discovered the benefits of the fucoxanthin compound<\/a> which is a type of carotenoid pigment found in brown seaweeds, such as Saccharina latissima. Also known as sugar kelp, the seaweed is cultivated in Europe and is available commercially.<\/p>\n GENIALG project is the result of a collaboration between IOTA Pharmaceuticals, a UK-based oncology SME, the University of York, UK, and the University of Cambridge, UK.<\/p>\n Dr David Bailey, Director of IOTA Pharmaceuticals, said: \u201cWe found that fucoxanthin not only inhibits cancer cell growth by itself, but also improves the effectiveness of certain (antiproliferative) pharmaceutical drugs. This means that treatment of human brain cancer cells with a combination of pharmaceutical drugs and a natural product extracted from seaweed could provide a new, more effective treatment option in targeting this challenging disease in certain contexts.\u201d<\/p>\n